REV3 rs465646 were associated with grade 3-4 hematologic toxicity in 663 NSCLC patients (OR = 2.54; 95% CI: 1.17–5.42; p = 0.016) (Ye et al., 2015). This evidence concerns the gene REV3L and non-small cell lung carcinoma.